

Tyenne® (tocilizumab-aazg) – First-time biosimilar launch

- On April 15, 2024, <u>Fresenius Kabi announced</u> the launch of <u>Tyenne (tocilizumab-aazg)</u> intravenous infusion, a biosimilar to Roche's Actemra (tocilizumab).
 - Tyenne is also FDA-approved as a subcutaneous injection. Launch of this product is pending.
 - In addition, Biogen's <u>Tofidence (tocilizumab-bavi)</u> received FDA approval of its intravenous infusion. Launch of this biosimilar product is pending.
- Tyenne and Actemra share the following indications in adult patients:
 - Moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs
 - Giant cell arteritis.
- Tyenne and Actemra share the following indications in patients 2 years of age and older:
 - Active polyarticular juvenile idiopathic arthritis
 - Active systemic juvenile idiopathic arthritis.
- Actemra is also indicated for the following:
 - Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosisassociated interstitial lung disease
 - Chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older
 - Coronavirus disease 2019 in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
- Like Actemra, Tyenne carries a boxed warning for risk of serious infections.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.